


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application.
 Deletions are ~~strikethrough~~ and additions are underlined.

1. (Currently amended) A compound represented by the following general-formula (I), the pharmaceutically acceptable salt or the isomer thereof:




wherein

X is an oxygen or sulfur atom;

A is an aminomethylene or methylene group;

B is a 4-*tert*-butylbenzyl, a 3,4-dimethylphenylpropyl, an oleyl or group wherein m is integer of 0 or 1 and n is 1 or 2;



R₁ is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfone or a lower alkylcarbonyl group having 1 to 5 carbon atoms;

R₂ is a hydrogen atom, a methoxy group or halogen atom;


R₃ is a hydrogen atom, a methoxy group or halogen atom;

R₄ is a hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms;

R₅ is a hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms;

R₆ is a lower alkyl group having 1 to 5 carbon atoms or a phenyl group.

2. (Currently amended) The compound according to claim 1 represented by the following general-formula (III), the pharmaceutically acceptable salt or the isomer thereof:




wherein

X is an oxygen atom or a sulfur atom;

R₁ is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfone or a lower alkylcarbonyl group having 1 to 5 carbon atoms;

R₂ is a hydrogen atom, a methoxyl group or a halogen atom;

R₃ is a hydrogen atom or a halogen atom;



3. (Original) The compound according to claim 2 wherein said compound is at least one selected from the group consisting of;

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[4-(methylsulfonylamino)benzyl]thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[3-methoxy-4-(methylsulfonylamino)benzyl]thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[3-chloro-4-(methylsulfonylamino)benzyl]thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[4-(methylsulfonylamino)-3-nitrobenzyl]thiourea,


N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[2-fluoro-4-(methylsulfonylamino)benzyl]thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[2-chloro-4-(methylsulfonylamino)benzyl]thiourea,

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[4-(methylsulfonylamino)benzyl]thiourea,

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[3-methoxy-4-(methylsulfonylamino)benzyl] thiourea,
 N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[3-fluoro-4-(methylsulfonylamino)benzyl] thiourea,
 N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[2-fluoro-4-(methylsulfonylamino)benzyl] thiourea,
 N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[2-chloro-4-(methylsulfonylamino)benzyl] thiourea,
 N-[2-(4-*tert*-butylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[4-(methylsulfonylamino)benzyl] thiourea, and
 N-[2-(4-*tert*-butylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[3-fluoro-4-(methylsulfonylamino)benzyl] thiourea.

4. (Currently amended) The compound according to claim 1 represented by the following general formula (IV), the pharmaceutically acceptable salt or the isomer thereof:




wherein

R_1 is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfone or a lower alkylcarbonyl group having 1 to 5 carbon atoms;


R_2 is a hydrogen atom, a methoxyl group or a halogen atom;

R_3 is a hydrogen atom or a halogen atom;



5. (Original) The compound according to claim 4 wherein said compound is N-(4-*tert*-butylbenzyl)-N-hydroxy-[4-(methylsulfonylamino)phenyl] acetamide.

6. (Currently amended) A compound represented by **general formula (II)**, the pharmaceutically acceptable salt or the isomer thereof:




wherein

X is an oxygen or sulfur atom;

B' is B or a secondary amine substituted with B,

wherein B is a 4-*tert*-butylbenzyl, a 3,4-dimethylphenylpropyl, an oleyl or



(II-1) group, wherein m is integer of 0 or 1 and n is 1 or 2;

R₁ is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfonyl group or lower alkylcarbonyl group having 1 to 5 carbon atoms;

R₂ is a hydrogen atom, a methoxy group or halogen atom;


R₃ is a hydrogen atom, a methoxy group or halogen atom;

R₄ is a hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms;

R₅ is a hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms;

R₆ is a lower alkyl group having 1 to 5 carbon atoms or a phenyl group.

7. (Currently amended) The compound according to claim 6 represented by **general formula (V)**, the pharmaceutically acceptable salt or the isomer thereof:





wherein

X is an oxygen atom or a sulfur atom;

R₁ is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfonyl group or lower alkylcarbonyl group having 1 to 5 carbon atoms;

R₂ is a hydrogen atom or a halogen atom;


R₃ is a hydrogen atom;

B is  ,  or  group.

8. (Currently amended) The compound according to claim 7 wherein said compound is at least one selected from the group consisting of;

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[4-(methylsulfonylamino)benzyl]thiourea,
 N-[2-(3,4-dimethylbenzyl)-3(pivaloyloxy)propyl]-N-hydroxy-N-[4-(methylsulfonylamino)benzyl]thiourea,
N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[4-(methylsulfonylamino)benzyl]urea, and
 N-[2-(3,4-dimethylbenzyl)-3(pivaloyloxy)propyl]-N-hydroxy-N-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea.

9. (Currently amended) The compound according to claim 6 represented by general formula (VI), the pharmaceutically acceptable salt or the isomer thereof:




wherein

R₁ is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfonyl group or lower alkylcarbonyl group having 1 to 5 carbon atoms;

R₂ is a hydrogen atom, a methoxyl group or a halogen atom;

R₃ is a hydrogen atom, a methoxyl group or a halogen atom;



10. (Original) The compound according to claim 9 wherein said compound is N-hydroxy-N-[4-(methylsulfonylamino)benzyl]-2-(4-*tert*-butylphenyl)acetamide.

11. (Currently amended) A pharmaceutical composition comprising the compound of general-formula (I) as set forth in claim 1 as an active ingredient in amount effective amount for an antagonist of vanilloid receptor together with pharmaceutically acceptable carriers or diluents.

12. (Currently amended) A pharmaceutical composition comprising the compound of general-formula (I) as set forth in claim 1 as an active ingredient in amount effective to alleviate or treat pain diseases or inflammatory diseases together with pharmaceutically acceptable carriers, excipients or diluents.

13. (Currently amended) A pharmaceutical composition comprising an efficient amount of the compound represented by general-formula (II) as set forth in claim 6 as an active ingredient in amount effective for an antagonist of vanilloid receptor together with pharmaceutically acceptable carriers or diluents.

14. (Currently amended) A pharmaceutical composition comprising the compound of general-formula (II) as set forth in claim 6 as an active ingredient in amount effective amount to alleviate or treat pain disease together with pharmaceutically acceptable carriers or diluents.

15. (Currently amended) The pharmaceutical composition according to claim 12 or 14 wherein said pain disease is at least one selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitivity, irritable bowel syndrome, a respiratory disorder such as asthma, or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence,

stomach-duodenal ulcer, inflammatory bowel disease caused by the vanilloid receptor antagonistic activity.

16. (Original) A pharmaceutical composition comprising the compound of any one of claims 1 to 10 as an active ingredient in amount effective for analgesic and anti-inflammation together with pharmaceutically acceptable carriers or diluents.

17. (Currently amended) A pharmaceutical composition comprising the compound of any one of claims 1 to 10 as an active ingredient together with pharmaceutically acceptable carriers or diluents for preventing and treating urgent urinary incontinence.

18. (Canceled)

19. (New) A method of treating pain disease and inflammatory disease by showing vanilloid receptor-antagonistic activity in a mammal comprising administering to said mammal an effective amount of the compound of any one of claims 1 to 10 together with a pharmaceutically acceptable carrier thereof.